Description

Tirzepatide – Research Grade Peptide

Description:
Tirzepatide, also known as Terzepatide, is a dual incretin agonist that activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism makes Tirzepatide a groundbreaking compound in metabolic research, offering insight into the synergistic roles of incretin hormones in regulating appetite, glucose homeostasis, and body weight.

Research Significance:

• GLP-1 receptor activation: Investigated for appetite suppression, delayed gastric emptying, enhanced insulin secretion, and improved glycemic control.
• GIP receptor activation: Studied for complementary effects on insulinotropic signaling, nutrient handling, and overall metabolic efficiency.

Potential Applications in Research:

• Modeling the effects of dual incretin agonism on energy balance and metabolism.
• Studying weight loss mechanisms through appetite regulation and caloric intake reduction.
• Exploring glucose and insulin dynamics in preclinical models of diabetes and obesity.
• Comparing dual agonist performance against single-pathway incretin analogues.

Background:
Early preclinical and clinical studies have demonstrated that Tirzepatide may produce substantial body-weight reduction and significant improvements in glycemic control. This has made it a focal point in obesity and diabetes research, where understanding combined GLP-1/GIP signaling could lead to breakthroughs in treating complex metabolic disorders.

Specifications:

• Compound: Tirzepatide (Terzepatide, Research Grade)
• Form: Lyophilized powder
• Storage: Store at -20°C in a dry, dark place
• Stability: Stable for extended periods when properly stored

Important Notice:
This product is supplied strictly for laboratory research use only. It is not intended for human or veterinary use. No therapeutic or diagnostic claims are made.